Infliximab - Latest Advances

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: September 25, 2025

Real-Life Durability and Risk Factors for Biologic Discontinuation in Pediatric Inflammatory Bowel Disease: Results from the Sigenp IBD Registry.

Journal: Journal of Crohn's & colitis

Published: September 19, 2025

A Case of Severe Immune Checkpoint Inhibitor-associated Gastritis Treated with Steroids and Infliximab.

Journal: Internal medicine (Tokyo, Japan)

Published: September 18, 2025

Treatment-associated posterior reversible encephalopathy syndrome in an adolescent with Crohn's disease: A case report.

Journal: Archivos argentinos de pediatria

Published: September 16, 2025

Pneumocystis jirovecii Pneumonia in Patients Without HIV, Transplant, or Cancer: Missed Opportunities for Prevention.

Journal: Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases

Published: September 16, 2025

Filters

Exploring Anti-TNF Therapy in Relapsing Polychondritis with Co-Existing Ulcerative Colitis: A Case Report and Literature Review.

Exploring Anti-TNF Therapy in Relapsing Polychondritis with Co-Existing Ulcerative Colitis: A Case Report and Literature Review.

Serum oncostatin M is a potential biomarker of disease activity and infliximab response in inflammatory bowel disease.

Serum oncostatin M is a potential biomarker of disease activity and infliximab response in inflammatory bowel disease.

Severe liver injury due to infliximab therapy and adalimumab.

Severe liver injury due to infliximab therapy and adalimumab.

No post-infusion reactions after infliximab or vedolizumab.

No post-infusion reactions after infliximab or vedolizumab.

Disease duration impacts intestinal gene expression profiles in crohn's disease but not in ulcerative colitis.

Disease duration impacts intestinal gene expression profiles in crohn's disease but not in ulcerative colitis.

Case Report: TNF-α Inhibitor-Associated Demyelinating Disease.

Case Report: TNF-α Inhibitor-Associated Demyelinating Disease.

Hypersensitivity reactions to biologics in chronic rheumatic diseases: prevalence and associated factors.

Hypersensitivity reactions to biologics in chronic rheumatic diseases: prevalence and associated factors.

Author's Reply: Comment on ``A switch to infliximab may be more effective than ustekinumab following adalimumab pharmacodynamic failure in paediatric patients with Crohn's disease''.

Author's Reply: Comment on ``A switch to infliximab may be more effective than ustekinumab following adalimumab pharmacodynamic failure in paediatric patients with Crohn's disease''.

Real-Life Durability and Risk Factors for Biologic Discontinuation in Pediatric Inflammatory Bowel Disease: Results from the Sigenp IBD Registry.

Real-Life Durability and Risk Factors for Biologic Discontinuation in Pediatric Inflammatory Bowel Disease: Results from the Sigenp IBD Registry.

A Case of Severe Immune Checkpoint Inhibitor-associated Gastritis Treated with Steroids and Infliximab.

A Case of Severe Immune Checkpoint Inhibitor-associated Gastritis Treated with Steroids and Infliximab.

Treatment-associated posterior reversible encephalopathy syndrome in an adolescent with Crohn's disease: A case report.

Treatment-associated posterior reversible encephalopathy syndrome in an adolescent with Crohn's disease: A case report.

Pneumocystis jirovecii Pneumonia in Patients Without HIV, Transplant, or Cancer: Missed Opportunities for Prevention.

Pneumocystis jirovecii Pneumonia in Patients Without HIV, Transplant, or Cancer: Missed Opportunities for Prevention.